CEVEC's CAP-GT sets a new standard through RCA-free production of adenoviral vectors for gene therapy applications
The technology is underway to replace HEK293 as current production host for adenoviral vectors.
CEVEC Pharmaceuticals has announced that the company's proprietary cell-expression system, CAP-GT, has delivered the production of safe adenoviral (AV) gene therapy vectors with the proven absence of RCAs.
For most adenoviral-based gene therapy applications, adenoviral vectors are modified in such a way to deliver the gene of interest to the target cell but cannot replicate within the cells of the patient. The commonly used producer cell line for vector production, HEK 293, bears the inherent risk of accidentally generating, by homologous recombination, replication-competent adenoviruses. The absence of RCAs in clinical production lots can only be proven through intensive testing to eliminate the risk of involuntarily spreading the infective vector.
CEVEC's CAP-GT prohibits the formation of RCAs as the CAP cells do not allow homologous recombination events to occur with the AV vector genome. No RCAs are found in 5 x 1010 virus particles (VP) of CAP-GT-derived adenoviral vectors, whereas adenoviral vector preparations from HEK293 cells contain 5-500 RCAs per 1010 VPs. RCA was measured using an in vitro assay. The observed titers in the CAP-GT derived adenoviral vector production results matched and exceeded titers seen in production when using HEK293 cells.
"We have delivered superior results with the production of CAP-GT-derived adenoviral vectors," commented Frank Ubags, CEO of CEVEC Pharmaceuticals GmbH. "The advantages in terms of safety and productivity, as well as the easy industrial scale up of the CAP-GT suspension cell lines, create an unique position in gene therapy vector manufacturing with the clear goal to replace HEK293 as the current production host."
CEVEC's CAP-GT technology meets the necessary regulatory requirements. Derived from a non-tumour human origin and grown in serum-free suspension culture, the cell line was developed according to industrial standards with complete documentation and full certification of materials. A master file is currently in process to be submitted to the FDA.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance